Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 3

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: focus on insulin glulisine

Authors Heather Ulrich, Benjamin Snyder, Satish K Garg

Published Date August 2007 Volume 2007:3(3) Pages 245—254

DOI

Published 15 August 2007

Heather Ulrich1,4, Benjamin Snyder1,Satish K Garg1,2,3

1Barbara Davis Center for Childhood Diabetes; 2Department of Medicine; 3Pediatrics; 4Department of Clinical Pharmacy, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA

Abstract: Normalization of blood glucose is essential for the prevention of diabetes mellitus (DM)-related microvascular and macrovascular complications. Despite substantial literature to support the benefits of glucose lowering and clear treatment targets, glycemic control remains suboptimal for most people with DM in the United States. Pharmacokinetic limitations of conventional insulins have been a barrier to achieving treatment targets secondary to adverse effects such as hypoglycemia and weight gain. Recombinant DNA technology has allowed modification of the insulin molecule to produce insulin analogues that overcome these pharmacokinetic limitations. With time action profiles that more closely mimic physiologic insulin secretion, rapid acting insulin analogues (RAAs) reduce post-prandial glucose excursions and hypoglycemia when compared to regular human insulin (RHI). Insulin glulisine (Apidra®) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. The quick absorption of insulin glulisine more closely reproduces physiologic first-phase insulin secretion and its rapid acting profile is maintained across patient subtypes. Clinical trials have demonstrated comparable or greater efficacy of insulin glulisine versus insulin lispro or RHI, respectively. Efficacy is maintained even when insulin glulisine is administered post-meal. In addition, glulisine appears to have a more rapid time action profile compared with insulin lispro across various body mass indexes (BMIs). The safety and tolerability profile of insulin glulisine is also comparable to that of insulin lispro or RHI in type 1 or 2 DM and it has been shown to be as safe and effective when used in a continuous subcutaneous insulin infusion (CSII). In summary, insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all BMIs and a worthy option for prandial glucose control in type 1 or 2 DM.

Keywords: glycemic control, glycosylated hemoglobin A1c (HbA1c), rapid-acting insulin analogues, type 1 diabetes mellitus, type 2 diabetes mellitus, insulin glulisine, body mass index (BMI)

Download Article [PDF] 

Readers of this article also read:

Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer

Su H, Luo Q, Xie H, Huang XF, Ni YH, Mou YB, Hu QG

International Journal of Nanomedicine 2015, 10:1921-1930

Published Date: 10 March 2015

Quantitative evaluation in combination with nonquantitative evaluation in early patellar cartilage osteoarthritis at 3.0 T

Zuo HD, Yao WW, Qu N, Yang SX, Wang JH, Cui XJ

Clinical Interventions in Aging 2014, 9:1133-1143

Published Date: 16 July 2014

Effect of whole-body vibration for 3 months on arterial stiffness in the middle-aged and elderly

Lai CL, Chen HY, Tseng SY, Liao WC, Liu BT, Lee MC, Chen HS

Clinical Interventions in Aging 2014, 9:821-828

Published Date: 12 May 2014

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia [Corrigendum]

Kinoshita Y, DiBonaventura M, Rossi B, Iwamoto K, Wang ECY, Briere JB

Clinical and Experimental Gastroenterology 2013, 6:193-194

Published Date: 23 September 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises

Alfieri FM, Riberto M, Gatz LS, et al

Clinical Interventions in Aging 2010, 5:363-364

Published Date: 24 November 2010

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

Odd Erik Johansen, Pål Johan Vanberg, Bente Kvarv Kilhovd, Anders Palmstrøm Jørgensen

Vascular Health and Risk Management 2009, 5:121-128

Published Date: 18 December 2008

Misregulation of rhodopsin phosphorylation and dephosphorylation found in P23H rat retinal degeneration

Yoshiyuki Saito, Hiroshi Ohguro, Ikuyo Ohguro, Noriyuki Sato, Futoshi Ishikawa, et al

Clinical Ophthalmology 2008, 2:821-828

Published Date: 30 October 2008

Dissection of the ascending thoracic aorta as a complication of percutaneous coronary intervention

Cihangir Uyan, Huseyin Arinc, Huseyin Gunduz, Ramazan Akdemir

Vascular Health and Risk Management 2008, 4:253-257

Published Date: 6 March 2008